OpenNashPodcasts

Topic

U.S. Food and Drug Administration

The U.S. Food and Drug Administration (FDA) is the U.S. agency that decides which drugs and medical products can enter the American market, and these podcasts cover its approvals, trial rules, and role in AI and healthcare. Dan Carpenter describes it as a veto player over which drugs reach the market.

Speakers recall specific decisions, such as the 2005 approval of Symlin and the 2024 approval of imetelstat. Others discuss how the agency handles AI tools, vaccines and Covid boosters. Scott Gottlieb, a former commissioner, and Robert Califf, who marked a year as commissioner around March 2023, appear among the voices.

73 facts from 27 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

1989

The FDA approved Oculinum's botulinum toxin for strabismus on December 29, 1989, through the orphan drug pathway.

“On December 29th, 1989, through an orphan drug approval pathway, Oculinum gets official FDA approval to manufacture and sell botulinum toxin for the treatment of strabismus.”

Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:16:18

2000s

Bancel says an FDA warning letter on Eli Lilly's injectable insulin manufacturing site held up Lilly's planned biologic launches, because those products were to be made in the same plant.

“because there was a warning letter on the injectable site that was making insulin, all the biologics needed to be injected as well.”

Stéphane Bancel · Ep11: Stephane Bancel, 0:18:06

2001

In July 2001 an FDA advisory committee voted 8-1 against approving Symlin for type 1 diabetes and 6-3 against for type 2.

“The panel votes 8-1 against approving the drug for type 1 diabetes. They vote 6-3 against type 2.”

Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:38:01

2004

Avastin, the first approved drug of this angiogenesis-blocking type, was approved by the FDA in 2004, 28 years after the 1976 work.

“in 2004, 28 years after we started, the first one of those, Avastin, got approved by the FDA.”

Bob Langer · #105 – Robert Langer: Edison of Medicine, 0:18:25

2004

Gottlieb says the emergency use authorization pathway originated in Project BioShield, post-9/11 legislation for rapid authorization of countermeasures to bioterrorist attacks.

“The emergency use authorization, which was originally derived in Project BioShield, it was sort of post-9 -11 legislation on how to create a pathway for the rapid regulatory authorization”

Scott Gottlieb · Uncontrolled Spread: Science, Policy, Institutions, Infrastructure, 0:08:38

2005

The FDA approved Symlin (pramlintide) on March 16, 2005, as the first new class of type 1 diabetes medicine since insulin.

“It's approved, and it's now the first new class of medicines approved for type 1 diabetes since the discovery of insulin itself 80 years earlier.”

Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:46:52

2014

On March 12, 2014, the FDA placed a full clinical hold on all imetelstat trials over liver toxicity, and Geron's stock fell more than 60 percent that day.

“On March 12, 2014, the FDA places a full clinical hold on all Amelstat trials.”

Matthew Pech · Episode #2: Geron, 1:42:48

2016

George Yancopoulos said the FDA approved 22 medicines in 2016, of which only eight were first in class.

“Last year, 2016, 22 medicines approved by the FDA. Only eight of them. Only eight of them first in class.”

George Yancopoulos · Ep3: George Yancopoulos, 0:09:04

2018

In 2018 the FDA authorized Digital Diagnostics' IDx-DR, described as the first FDA authorization of an autonomous AI that works without physician input.

“Back in 2018, the FDA issued authorization for your company's device, which I understand was the first FDA authorization for an autonomous AI without physician input.”

Arjun Manrai · No Doctor Needed? Dr. Michael Abramoff on the Potential of Autonomous AI, 0:11:49

2020

Andrew von Eschenbach says the FDA approved clinical trials using the body's immune system, including natural killer cells, against the coronavirus.

“FDA has approved clinical trials to use our own body's immune system, including using natural killer cells that are already in our body.”

Andrew von Eschenbach · Ep. 8: Legacy, with former FDA Commissioner Andrew von Eschenbach, 0:08:11

2020

Gottlieb says the FDA required the full trial data set and two months of follow-up on half the patients before authorizing COVID-19 vaccines.

“the FDA moved towards a posture where they required the full data set and two months of follow-up on 50 % of the patients in the clinical trial before they would authorize the vaccines.”

Scott Gottlieb · Uncontrolled Spread: Science, Policy, Institutions, Infrastructure, 0:10:15

2021

Acting FDA Commissioner Janet Woodcock said the high-exposure group for Pfizer boosters includes teachers, daycare workers, grocery workers, and people in prisons and homeless shelters.

“Dr. Janet Woodcock, the acting FDA commissioner, specified in the FDA's release that includes folks like teachers, daycare workers, grocery store workers, and people who are in prisons and homeless shelters.”

Meg Terrell · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:04:54

2021

Amy Abernethy says the FDA issued three core guidances on real-world data at the end of 2021, informed by the collaborative process she described.

“That then informed the guidance that came out from FDA at the end of 2021. There were three core guidances around robot data, all informed by that process.”

Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:11:30

2021

Amy Abernethy says the FDA published an action plan for AI-based medical software around January 2021.

“And I think it was like around January 2021, put out an action plan to specify, here are the details of what we think good's going to look like in this space.”

Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:19:11

2021

Amy Abernethy says the FDA's AI action plan called for good software design and an easy way to understand an AI product's output.

“We need, you know, good software design. We need to make sure that there is an easy way to understand the output of an AI-based product”

Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:19:11

2023

A CRISPR-based sickle cell therapy was the first CRISPR therapeutic up for FDA approval at the time of recording.

“Geneticists made use of that function to develop a cure for sickle cell disease, which is currently the first CRISPR-based therapeutic up for approval by the FDA.”

Bapu Jena · 72. What’s Stopping Us From Curing Rare Diseases?, 0:24:15

2024

On March 14, 2024, the FDA's Oncology Drugs Advisory Committee voted 12 to 2 that imetelstat's benefits outweigh its risks.

“On March 14, 2024, FDA's Oncology Drugs Advisory Committee votes 12 to 2 that the benefits of the metal stat outweigh its risk.”

Matthew Pech · Episode #2: Geron, 1:49:53

2024

On June 6, 2024, the FDA approved imetelstat for low-risk myelodysplastic syndromes, making it the first approved telomerase inhibitor.

“And on June 6, 2024, the FDA ultimately approves metal stat, now called Rotello, for its use in low-risk MDS.”

Matthew Pech · Episode #2: Geron, 1:50:28

Undated

Andrew von Eschenbach says that while he led the FDA, much production of drug ingredients, excipients and gelatin capsules took place outside the United States.

“the production of, for example, active pharmaceutical ingredients and excipients, even the gelatin that you find your medicines encapsulated in, and many other things were occurring and being developed outside the United States.”

Andrew von Eschenbach · Ep. 8: Legacy, with former FDA Commissioner Andrew von Eschenbach, 0:13:54

Undated

Under Andrew von Eschenbach, the FDA created its 'Beyond Our Borders' program and placed personnel and offices in China, India, Europe, Central America and later the Middle East.

“we created FDA Beyond Our Borders and actually put FDA personnel and offices in China, in India, in Europe, in Central America, and eventually in the Middle East.”

Andrew von Eschenbach · Ep. 8: Legacy, with former FDA Commissioner Andrew von Eschenbach, 0:14:35

Undated

Langer says engineered skin has been approved by the FDA.

“skin's already been made and approved by the FDA. There are advanced clinical trials, like what are called phase three trials”

Bob Langer · #105 – Robert Langer: Edison of Medicine, 0:31:11

Undated

The CRISPR treatment that cured Jimmy Olaher's sickle cell disease is the first CRISPR-based therapeutic up for approval by the U.S. FDA.

“The treatment that cured Jimmy's sickle cell disease is now the first CRISPR-based therapeutic up for approval by the FDA, meaning it could hit the market as early as this year.”

Bapu Jena · 73. Who Pays for Multimillion-Dollar Miracle Cures?, 0:06:00

Undated

Andrew Lowe says FDA approval of a new drug generally takes about 5 to 15 years, depending on the disease.

“the FDA approval process generally takes on the order of 5 to 15 years, depending on the nature of the disease.”

Andrew Lowe · 73. Who Pays for Multimillion-Dollar Miracle Cures?, 0:12:06

Undated

Amy Abernethy says the Evidence Accelerator brought the FDA and innovators together so regulators could say which evidence they trusted and what they wanted to know more about.

“We called this the evidence accelerator. And regulators and others could say, I trust this, I don't trust that, here's what I want to know more about.”

Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:07:13

Undated

Amy Abernethy says AI-based products can be regulated under the FDA's traditional device framework, such as diagnostics or software as a medical device.

“We can regulate them according to the traditional device framework, whether that's a diagnostic or a software as a medical device.”

Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:18:08

Undated

Amy Abernethy says companies traditionally submit clinical trial results to the FDA as hundreds of pages of reports and then wait for questions.

“you ultimately package up the clinical trial, write hundreds of pages of reports, and ultimately ship that over the FDA and wait for questions to come back.”

Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:20:47

Undated

Amy Abernethy says that while at the FDA she worked on infrastructure so companies could push data directly to the agency instead of submitting lengthy reports.

“we were building the pipes at FDA to be ready for a landscape where really all you do is push your data across over FDA and FDA is ready to receive”

Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:21:23

Undated

Andrew Huberman says the FDA decided NMN could no longer be sold as a supplement because a clinical trial had been started on it.

“the FDA decided that it should not be sold over the counter, um, anymore because there was a clinical trial initiated on NMN”

Andrew Huberman · Supplements for Longevity & Their Efficacy | Dr. Peter Attia, 1:36:15

Undated

Farrugia says a company's epilepsy algorithm showed weaker performance in one population group when tested on Mayo's Validate, was corrected, and then went on to gain FDA approval.

“a company that had an epilepsy algorithm performed really great but there was one section of the population where it didn't do as well and they were able to go back change that and get fda”

Gianrico Farrugia · Healthcare at an inflection point - Mayo Clinic CEO Dr. Gianrico Farrugia, 0:16:31

Undated

The FDA worked with Moderna on approval of the COVID vaccine, which Brice Challamel describes as the first mRNA product to reach the American market.

“They were an amazing partner to Moderna in the approval process of the very first mRNA product ever to go to market in America, which was the COVID vaccine.”

Brice Challamel · #249 Brice Challamel: How Moderna is Using AI to Disrupt Modern Healthcare, 0:28:54

Undated

Dan Carpenter says phase three trials are large randomized clinical trials assessing efficacy and are very expensive for companies.

“phase three involves a much more direct and large-scale attack if you will or assessment of efficacy and that's where you get the sort of large randomized clinical trials that are very expensive”

Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:04:33

Undated

Dan Carpenter explains that surrogate endpoints, such as tumor measurements, are used for cancer drugs because waiting to see who survives longer can delay decisions.

“the idea is that a cancer drug, we really want to know whether that drug saves lives. But if we wait to see whose lives are saved or prolonged by that drug, we might miss the opportunity”

Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:08:02

Undated

An IND, or Investigational New Drug Application, is the submission sent to the U.S. FDA explaining a drug before clinical trials can begin.

“IND is Investigational New Drug Application. And in the United States, that is the submission that you have to send to FDA explaining your drug to them effectively”

Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:11:38

Undated

Brandon Rice says NDA paperwork was once shipped to the FDA in a semi-truck, and that electronic PDF submission kept the same volume of paper.

“it used to be that you would fill the back of a semi-truck with all of the paperwork for your NDA, that market approval application I mentioned, and you would literally ship it to FDA.”

Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:18:39

Undated

Brandon Rice contrasts regulation in many industries, which he likens to a fence with fines for stepping outside, with drug regulation, which he likens to a railroad.

“In many industries, it's a fence around what you're allowed to do. And if you step outside that fence, you get fined.”

Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:09:31

Undated

Andy Beam says the FDA previously expressed willingness to accept computational models of antibody designs in place of animal models.

“the FDA previously said they would express willingness for computational models of antibody designs instead of animal models”

Andrew Beam · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:29:26

Undated

Bancel said he expects the treatment to be approved as a process-based biologics license application, as CAR-T therapies were, rather than as a fixed product.

“CAR-T was also approved in the same way as we believe this one will be, which is as a process BLA, not a product BLA.”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:28:11

Undated

Bancel said Moderna has five approved products, but its individualized cancer treatment has been handled with a process IND since it entered the clinic.

“Moderna has five product approved. So that's really product approval. On this one, the whole process since we started in the clinic, the IND was a process IND.”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:28:11

Undated

Daphne Koller says between 9 and 22 percent of diseases have any FDA-approved therapeutic.

“the fraction of diseases that have any FDA-approved therapeutic, even if it's addressing purely symptoms, depending on whose estimates you believe, it's somewhere between 9 % to 22%”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:05:36

Episodes